IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes

Overview of attention for article published in JCI Insight, November 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (79th percentile)
Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

twitter: 11 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 63 Mendeley

So far, Altmetric has seen 12 X posts from 11 X users, with an upper bound of 102,454 followers.

RT @HatragyiSafarne: IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes. #type1diabetes #Tocilizumab https://t.c…

#ClinicalMedicine: IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes: https://t.co/Qh1NJOKeVV @UCSF #Endocrinology #Immunology

IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes @JCI_insight https://t.co/LU3xqBPRHh

IL-6R blockade failed in clinic... Sorry for patients with T1D https://t.co/VHTlpCs1Fm

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 8 additional X posts.